Frontlight ResearchEarly access
Spinal muscular atrophy trials in United States
9 of 17 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Where
- Boston, Norfolk, Palo Alto
- Age
- 15 years to 60 years
- People
- 90 worldwide
- Run by
- Biogen
See details and how to joinNCT07444476 - No phaseTaking peopleStudy of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
- Where
- Austin, Baltimore, Boston, Charlottesville, Chicago, Cleveland, Grand Rapids, Hershey, Houston, New York, Norfolk, Orange, Orlando, Palo Alto, Philadelphia, Phoenix, San Diego
- Age
- 3 years and over
- People
- 90 worldwide
- Run by
- Alcyone Therapeutics, Inc
See details and how to joinNCT05866419 - Phase 4Taking peopleASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
- Where
- Boston, Columbus, Little Rock, New York, Philadelphia, Stanford
- Age
- 2 years to 100 years
- People
- 36
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07448610 - Phase 3Taking peopleA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Where
- Chicago, Flower Mound, Norfolk
- Age
- 0 days to 42 days
- People
- 30 worldwide
- Run by
- Biogen
See details and how to joinNCT07221669 · EU 2025-524054-34-00 - No phaseTaking peopleHABIT-ILE + FST in Children With SMA: Preliminary Effectiveness
- Where
- New York
- Age
- 5 years to 17 years
- People
- 20
- Run by
- Teachers College, Columbia University
See details and how to joinNCT07488338 - Phase 3Taking peopleA Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
- Where
- Flower Mound
- Age
- 0 days to 7 months
- People
- 42 worldwide
- Run by
- Biogen
See details and how to joinNCT07444450 · EU 2025-523857-32-00 - Phase 2Taking peopleA Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
- Where
- Baltimore, Boston, Chicago, Columbia, Flower Mound, Hartford, Hillsborough, Houston, Iowa City, Kissimmee, Little Rock, New York, Norfolk, Philadelphia, San Diego, Stanford
- Age
- 5 years to 17 years
- People
- 60 worldwide
- Run by
- argenx
See details and how to joinNCT07287982 · EU 2025-523496-32-00 - Phase 2Taking peopleA Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- Where
- Atlanta, Aurora, Dallas, Flower Mound, Fort Worth, Grand Rapids, Houston, Iowa City, Orange, Palo Alto, Philadelphia, Phoenix
- Age
- Up to 2 years
- People
- 52 worldwide
- Run by
- Scholar Rock, Inc.
See details and how to joinNCT07047144 - Phase 1Taking peopleA Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
- Where
- Boston, Charlottesville, Chicago, Grand Rapids, Hershey, Houston, Norfolk, Orange, Orlando, Palo Alto, Philadelphia, Phoenix
- Age
- 3 years and over
- People
- 78 worldwide
- Run by
- Biogen
See details and how to joinNCT06555419 · EU 2024-514239-21-00